Perioperative Immune Checkpoint Inhibitors Combined with Radical Cystectomy: A Rapid Systematic Review and Meta-analysis - PubMed
a day ago
- #Immune checkpoint inhibitors
- #Muscle-invasive bladder cancer
- #Perioperative therapy
- Perioperative immune checkpoint inhibitors (ICIs) combined with radical cystectomy (RC) are emerging as a treatment for muscle-invasive bladder cancer (MIBC).
- A meta-analysis of five randomized controlled trials (RCTs) showed benefits in disease-free survival for lower tract urothelial carcinoma (LTUC) with adjuvant-only ICIs.
- Perioperative ICIs demonstrated improved event-free survival and overall survival for LTUC patients.
- Grade ≥3 treatment-related adverse events occurred in 16-26% of adjuvant-only trials and 41-71% in perioperative trials.
- High heterogeneity in trial designs and treatment strategies limits the interpretability of the results.
- Further research is needed to optimize patient selection, treatment sequencing, and combination strategies for MIBC.